Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics, on Notice from Nasdaq, Plans to Appeal Decision

NEW YORK, Jan. 29-Joining the small crowd of genomics firms that are on the verge of losing a spot on the trading floor, Paradigm Genetics said today that Nasdaq notified the company on Jan. 24 that it is now subject to delisting.


Paradigm's stock has been trading below the benchmark $1 minimum bid price since Oct. 1. By Nasdaq rules, if a company is priced under that cutoff for more than 30 consecutive trading days, it has 90 days to boost its stock price or risk being evicted from the exchange.


The company plans to appeal the determination, and its stock will continue to be traded on the exchange pending that decision.


Paradigm Genetics is also considering a transfer to Nasdaq's small cap market, which would give the company more time to hike its share price back above the $1 limit.


Earlier this month, the company said it was selling off its ParaGencrop science division to a Canadian crop shop in a deal expected to close by mid-February.


Other firms on the Nasdaq warning list include Deltagen, Lynx Therapeutics, and Orchid Biosciences.



The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.